The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
All-Cause Mortality in Randomized Trials of Cancer Screening
Abstract
BACKGROUND: The most widely accepted end point in randomized cancer screening trials is disease-specific mortality. The validity of this end point, however, rests on the assumption that cause of death can be determined accurately. An alternative end point is all-cause mortality, which depends only on the accurate ascertainment of deaths and when they occur. We compared disease-specific and all-cause mortality in published randomized cancer-screening trials to indirectly assess the validity of the disease-specific mortality end point. METHODS: We examined all 12 published randomized trials of cancer screening for which both end points were available (seven of mammography, three of fecal occult blood detection, and two of chest x-ray screening for lung cancer). For each randomized trial, we subtracted disease-specific mortality observed in the screened group from that observed in the control group and all-cause mortality in the screened group from that in the control group. We then compared the differences in these two mortality measures. RESULTS: In five of the 12 trials, differences in the two mortality rates went in opposite directions, suggesting opposite effects of screening. In four of these five trials, disease-specific mortality was lower in the screened group than in the control group, whereas all-cause mortality was the same or higher. In two of the remaining seven trials, the mortality rate differences were in the same direction but their magnitudes were inconsistent; i.e., the difference in all-cause mortality exceeded the disease-specific mortality in the control group. Thus, results of seven of the 12 trials were inconsistent in their direction or magnitude. CONCLUSION: Major inconsistencies were identified in disease-specific and all-cause mortality end points in randomized cancer screening trials. Because all-cause mortality is not affected by bias in classifying the cause of death, it should be examined when interpreting the results of randomized cancer-screening trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 8,990
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood
Mandel, J. S., Bond, J. H., Church, T. R., Snover, D. C., Bradley, G. M., Schuman, L. M., & Ederer, F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305133281901 · Cited by 3,229
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Hardcastle, J. D., Chamberlain, J. O., Robinson, M. H., Moss, S. M., Amar, S. S., Balfour, T. W., James, P. D., & Mangham, C. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03386-7 · Cited by 2,793
Randomised study of screening for colorectal cancer with faecal-occult-blood test
Kronborg, O., Fenger, C., Olsen, J., Jørgensen, O. D., & Søndergaard, O. (1996) · The Lancet · doi:10.1016/s0140-6736(96)03430-7 · Cited by 2,501
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
(2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,007
Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
Andersson, I., Aspegren, K., Janzon, L., Landberg, T., Lindholm, K., Linell, F., Ljungberg, O., Ranstam, J., & Sigfússon, B. (1988) · BMJ · doi:10.1136/bmj.297.6654.943 · Cited by 916
Is screening for breast cancer with mammography justifiable?
Gøtzsche, P. C., & Olsen, O. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06065-1 · Cited by 853
Miller, A. B., Baines, C. J., To, T. M., & Wall, C. (1992) · Europe PMC (PubMed Central) · Cited by 744
Screening for Early Lung Cancer
Melamed, M. R., Flehinger, B. J., Zaman, M. B., Heelan, R. T., Perchick, W. A., & Martini, N. (1984) · Chest · doi:10.1378/chest.86.1.44 · Cited by 538
RANDOMISED, CONTROLLED TRIAL OF FAECAL OCCULT BLOOD SCREENING FOR COLORECTAL CANCER
Hardcastle, J. D., Chamberlain, J., Sheffield, J., Balfour, T. W., Armitage, N. C., Thomas, W. M., Pye, G., James, P. D., Amar, S. S., & Moss, S. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92750-5 · Cited by 529
Lung Cancer Mortality in the Mayo Lung Project: Impact of Extended Follow-up
Marcus, P. M., Bergstralh, E. J., Fagerstrom, R. M., Williams, D. E., Fontana, R., Taylor, W. F., & Prorok, P. C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1308 · Cited by 522
Miller, A. B. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.18.1490 · Cited by 512
Accuracy of Death Certificates for Coding Coronary Heart Disease as the Cause of Death
Lloyd-Jones, D. M., Martin, D. O., Larson, M. G., & Levy, D. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00005 · Cited by 480
Edinburgh trial of screening for breast cancer: mortality at seven years
HUGGINS, A. (1990) · The Lancet · doi:10.1016/0140-6736(90)90066-e · Cited by 445
Periodic Screening for Breast Cancer: The Health Insurance Plan Project and Its Sequelae, 1963-1986
Miller, A. B., Shapiro, S., Venet, W., Strax, P., & Venet, L. (1989) · Journal of Public Health Policy · doi:10.2307/3342801 · Cited by 438
(1993) · Cancer Causes and Control · doi:10.1007/bf00052433 · Cited by 437
Perceptions of Breast Cancer Risk and Screening Effectiveness in Women Younger Than 50 Years of Age
Black, W. C., Nease, R. F., & Tosteson, A. N. A. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.720 · Cited by 406
Self-citationTabar, L., Fagerberg, G., Duffy, S. W., & Day, N. E. (1989) · Journal of Epidemiology and Community Health · doi:10.1136/jech.43.2.107 · Cited by 355
Kubik, A., Parkin, D. M., Khlat, M., Erban, J., Polak, J., & Adamec, M. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450107 · Cited by 258
Feuer, E. J., Merrill, R. M., & Hankey, B. F. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.12.1025 · Cited by 251
Followup after 11 years – update of mortality results in the Stockholm mammographic screening trial
Frisell, J., Lidbrink, E., Hellström, L., & Rutqvist, L.-E. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005872617944 · Cited by 223
Accuracy of death certificate completion: the need for formalized physician training
Messite, J. (1996) · JAMA · doi:10.1001/jama.275.10.794 · Cited by 219
Causes of Death in Elderly Prostate Cancer Patients and in a Comparison Nonprostate Cancer Cohort
Newschaffer, C. J., Otani, K., McDonald, M. K., & Penberthy, L. T. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.8.613 · Cited by 214
'Inaccuracy' in death certification - where are we now?
Maudsley, G., & Williams, E. M. I. (1996) · Journal of Public Health · doi:10.1093/oxfordjournals.pubmed.a024463 · Cited by 183
Earlier diagnosis and survival in lung cancer
Brett, G. Z. (1969) · BMJ · doi:10.1136/bmj.4.5678.260 · Cited by 177
Health policy on blood cholesterol. Time to change directions.
Hulley, S. B., Walsh, J. M., & Newman, T. B. (1992) · Circulation · doi:10.1161/01.cir.86.3.1026 · Cited by 171
Cancer Screening in Theory and in Practice
Brawley, O. W., & Kramer, B. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.107 · Cited by 157
Kramer, B. S., Gohagan, J. K., & Prorok, P. C. (2021) · CRC Press eBooks · doi:10.1201/9780429179587 · Cited by 48
Screening Theory and Study Design: The Basics
Prorok, P. C., Kramer, B. S., & Gohagan, J. K. (2021) · CRC Press eBooks · doi:10.1201/9780429179587-5 · Cited by 6
(1998) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(19980701)83:1 · Cited by 3
Cited by
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Breast Cancer Screening: A Summary of the Evidence for the U.S. Preventive Services Task Force
Humphrey, L. L., Helfand, M., Chan, B. K. S., & Woolf, S. H. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_1-200209030-00012 · Cited by 1,137
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Isaacs, C., Kvale, P. A., Reding, D. J., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr500 · Cited by 1,121
Hewitson, P., Glasziou, P., Watson, E., Towler, B., & Irwig, L. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01875.x · Cited by 990
Moynihan, R., G⊘tzsche, P. C., Heath, I., & Henry, D. (2002) · BMJ · doi:10.1136/bmj.324.7342.886 · Cited by 900
Metadata
- Authors
- Black, W. C.
- Venue
- CancerSpectrum Knowledge Environment
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-02-06
- Volume
- 94
- Issue
- 3
- Pages
- 167-173
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2120488811
- Cited by
- 390
- References
- 34
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.